MAP2K7 and neurofibromatosis type 1: Our comprehensive and systematic study, using fibroblasts from Korean NF1 patients harboring PTC, demonstrated that ataluren decreased GTP‐bound RAS activity by 22.7% in NF1NS/+ fibroblasts and MEK‐ERK activity in 23.8% of NF1NS/+ fibroblasts.